Avista Capital Partners takes majority stake in Vision Healthcare
Context
The acquisition of Vision Healthcare NV by Avista Capital Partners marks a significant milestone in the company's strategic journey. The partnership enables Vision to realize further rapid growth and make additional investments that leverage its differentiated direct-to-consumer business model. With Avista's expertise and resources, Vision is well-positioned to expand its geographic reach and accelerate its acquisition strategy into the global direct-to-consumer healthcare market. The transaction also allows Vision to benefit from Avista's experience in the consumer healthcare sector, providing operational guidance and financial resources to drive growth and performance. As the consumer healthcare market continues to evolve, Vision is poised to take advantage of the growing demand for preventive health solutions and direct-to-consumer experiences, and the partnership with Avista will play a critical role in supporting the company's ambitious growth plans.
Vision Healthcare, which reported an EBITDA margin of [members only] in 2020, is valued in this transaction at an EV/EBITDA multiple of 10x–18x.
-> Deep-dive in Healthcare & Pharma market trends
Target
Vision Healthcare NV is a Belgium-based consumer healthcare platform with sales and operations across continental Europe. The company owns and markets a large branded portfolio of self-care and over-the-counter products, utilizing an omni-channel approach with a specific focus on online and direct-to-consumer channels. Founded in 2017, Vision has rapidly grown through a combination of successful buy-and-build strategies and strong organic growth in its direct-to-consumer businesses. With a strong focus on innovation and customer satisfaction, Vision aims to provide high-quality healthcare products and services to its customers. The company's mission is to become a leading player in the European consumer healthcare market, and it is well-positioned to take advantage of the growing demand for preventive health solutions and direct-to-consumer experiences.
Ent. Value
€300–700M
Equity Value
[members only]
Multiples
EV / Revenue
1x–3x
EV / EBITDA
10x–18x
EV / EBIT
[members only]
Historical Financials (EUR)
Similar deals in Life Sciences
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 09/2020 | EQT PARTNERS | SCHÜLKE | GERMANY | Medical Consumables |
| 09/2020 | PERMIRA | NEURAXPHARM | GERMANY | Generics / Labs |
| 04/2020 | ROYAL DSM | GLYCOM | DENMARK | Nutrition & Dietary Supplements |
| 04/2020 | AMERICAN SECURITIES | PARAGON MEDICAL | UNITED STATES | Medical Devices |
| 04/2020 | WARBURG PINCUS | POLYPLUS | FRANCE | R&D Biotech |
| 03/2020 | LBO FRANCE | DUTSCHER | FRANCE | Medical Consumables |
| 02/2020 | TETHYS INVEST / PSP INVESTMENTS / MITSUI & CO | CEVA SANTE ANIMALE | FRANCE | Animal Health |
| 02/2020 | PERRIGO COMPANY | HIGH RIDGE BRANDS (ORAL CARE PORTFOLIO) | UNITED STATES | Generics / Labs |
| 10/2019 | DENTRESSANGLE | MARLE GROUP | FRANCE | Implants & Prosthetics |
| 09/2019 | SAGARD | STERIMED | FRANCE | Medical Consumables |
REFERENCES
Valuation range: EV €300–700M
Revenue range: €100–200M
EBITDA range: €10–30M
EV/Revenue range: 1x - 3x
EV/EBITDA range: 10x - 18x
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of Vision Healthcare by Avista Capital Partners are reserved for mynth community members. Register for free to unlock full data.
Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.
Target: vision healthcare
FAQ
What transaction does this page cover?
How was the acquisition of Vision Healthcare by Avista Capital Partners valued, and what multiples were paid?
What were Vision Healthcare’s revenue and EBITDA at the time of the deal?
What sources support the information on this transaction?
What is mynth?